| 1 |
Komatsu Y, Takehara M, Hart X, et al. Advancements in non-dopaminergic treatments for schizophrenia: a systematic review of pipeline developments[J]. Pharmacopsychiatry, 2024, 57 (5): 221- 231.
doi: 10.1055/a-2307-6484
|
| 2 |
Kinon BJ, Leucht S, Tamminga C, et al. Rationale for adjunctive treatment targeting multiple mechanisms in schizophrenia [J]. J Clin Psychiatry, 2024, 85(3): 23nr15240.
|
| 3 |
Paul SM, Yohn SE, Popiolek M, et al. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia[J]. Am J Psychiatry, 2022, 179 (9): 611- 627.
doi: 10.1176/appi.ajp.21101083
|
| 4 |
Vasiliu O, Budeanu B, Cătănescu MȘ. The new horizon of atipsychotics beyond the classic dopaminergic hypothesis—the case of the xanomeline–trospium combination: a systematic review[J]. Pharmaceuticals, 2024, 17 (5): 610.
doi: 10.3390/ph17050610
|
| 5 |
Palma JA. Muscarinic control of cardiovascular function in humans: a review of current clinical evidence[J]. Clin Auton Res, 2024, 34 (1): 31- 44.
doi: 10.1007/s10286-024-01016-5
|
| 6 |
Correll CU, Abi-Dargham A, Howes O. Emerging treatments in schizophrenia [J]. J Clin Psychiatry, 2022, 83(1): SU21024IP21021.
|
| 7 |
Xin R, Chen Z, Fu J, et al. Xanomeline protects cortical cells from oxygen-glucose deprivation via inhibiting oxidative stress and apoptosis[J]. Front Physiol, 2020, 11, 656.
doi: 10.3389/fphys.2020.00656
|
| 8 |
Paul SM, Yohn SE, Brannan SK, et al. Muscarinic receptor activators as novel treatments for schizophrenia[J]. Biol Psychiatry, 2024, 96 (8): 627- 637.
doi: 10.1016/j.biopsych.2024.03.014
|
| 9 |
Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease[J]. Arch Neurol, 1997, 54 (4): 465- 473.
doi: 10.1001/archneur.1997.00550160091022
|
| 10 |
Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial[J]. Lancet, 2024, 403 (10422): 160- 170.
doi: 10.1016/S0140-6736(23)02190-6
|
| 11 |
Breier A, Brannan SK, Paul SM, et al. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results[J]. Psychopharmacology (Berl), 2023, 240 (5): 1191- 1198.
doi: 10.1007/s00213-023-06362-2
|
| 12 |
Administration USFaD. COBENFY (xanomeline and trospium chloride) capsules, for oral use Initial U. S. Approval: 2024 [EB/OL]. (2024-09) [2024-12-09]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216158s000lbl.pdf.
|
| 13 |
Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia[J]. N Engl J Med, 2021, 384 (8): 717- 726.
doi: 10.1056/NEJMoa2017015
|
| 14 |
Sauder C, Allen LA, Baker E, et al. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study[J]. Transl Psychiatry, 2022, 12 (1): 491.
doi: 10.1038/s41398-022-02254-9
|
| 15 |
Weiden PJ, Breier A, Kavanagh S, et al. Antipsychotic efficacy of KarXT (Xanomeline-Trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study [J]. J Clin Psychiatry, 2022, 83(3): 21m14316.
|
| 16 |
Kaul I, Sawchak S, Walling DP, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial[J]. JAMA Psychiatry, 2024, 81 (8): 749- 756.
doi: 10.1001/jamapsychiatry.2024.0785
|
| 17 |
Wright AC, McKenna A, Tice JA, et al. A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia[J]. Schizophr Res, 2024, 274, 212- 219.
doi: 10.1016/j.schres.2024.09.023
|
| 18 |
Leber A, Ramachandra R, Ceban F, et al. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review[J]. Expert Opin Pharmacother, 2024, 25 (4): 467- 476.
doi: 10.1080/14656566.2024.2334424
|
| 19 |
Horan WP, Targum SD, Claxton A, et al. Efficacy of KarXT on negative symptoms in acute schizophrenia: a post hoc analysis of pooled data from 3 trials[J]. Schizophr Res, 2024, 274, 57- 65.
doi: 10.1016/j.schres.2024.08.001
|
| 20 |
Nathan PJ, Millais SB, Godwood A, et al. A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease[J]. Alzheimers Dement (N Y), 2022, 8 (1): e12273.
doi: 10.1002/trc2.12273
|
| 21 |
Sparacino G, Verdolini N, Vieta E, et al. Existing and emerging pharmacological approaches to the treatment of mania: a critical overview[J]. Transl Psychiatry, 2022, 12 (1): 169.
doi: 10.1038/s41398-022-01928-8
|
| 22 |
Sutera N. Xanomeline-Trospium in schizophrenia: a detailed review and comparison with the Institute for Clinical and Economic Review's analysis[J]. J Manag Care Spec Pharm, 2024, 30 (6): 629- 632.
|
| 23 |
Correll CU, Angelov AS, Miller AC, et al. Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia[J]. Schizophrenia (Heidelb), 2022, 8 (1): 109.
doi: 10.1038/s41537-022-00320-1
|
), 刘小琳1, 周亚楠1, 翟金国2,*(
